The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

Jennifer Frederick didn't understand why she had a growing lump under her skin. A doctor returned a devastating diagnosis.

In the battle against aggressive breast cancer, a once-elusive target is now within reach—thanks to a breakthrough from a ...

Groundbreaking AI tool could diagnose skin cancer early in remote areas - The new tool is intended to enable early detection ...

A groundbreaking AI tool developed by a PhD student in Scotland aims to provide life-saving skin cancer diagnoses in places without internet access. Could this innovation revolutionize health care ...

Relative to existing gene signatures, the STRESS signature better predicted not only whether cells would later develop into ...